Madrigal Pharmaceuticals Inc’s recently made public that its Director REBECCA TAUB acquired Company’s shares for reported $15.12 million on Aug 12 ’25. In the deal valued at $349.50 per share,43,263 shares were bought.
Then, PAUL FRIEDMAN bought 43,605 shares, generating $15,239,948 in total proceeds.
Before that, PAUL FRIEDMAN bought 3,203 shares. Madrigal Pharmaceuticals Inc shares valued at $1,107,373 were divested by the Director at a price of $345.73 per share.
B. Riley Securities upgraded its Madrigal Pharmaceuticals Inc [MDGL] rating to a Buy from a a Neutral in a research note published on February 28, 2025; the price target was increased to $422 from $236. A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who remained covering the stock and in late February has reiterated a ‘”a Buy”‘ rating for it. Cantor Fitzgerald began covering MDGL with “Neutral” recommendation on June 28, 2024. Wolfe Research started covering the stock on June 11, 2024. It rated MDGL as “an Outperform”.
Price Performance Review of MDGL
On Tuesday, Madrigal Pharmaceuticals Inc [NASDAQ:MDGL] saw its stock jump 2.72% to $359.0. Over the last five days, the stock has gained 5.93%. Madrigal Pharmaceuticals Inc shares have risen nearly 47.35% since the year began. Nevertheless, the stocks have risen 16.34% over the past one year. While a 52-week high of $377.46 was reached on 02/26/25, a 52-week low of $200.63 was recorded on 05/27/25.
Levels Of Support And Resistance For MDGL Stock
The 24-hour chart illustrates a support level at 351.92, which if violated will result in even more drops to 344.85. On the upside, there is a resistance level at 363.03. A further resistance level may holdings at 367.07.
How much short interest is there in Madrigal Pharmaceuticals Inc?
A steep rise in short interest was recorded in Madrigal Pharmaceuticals Inc stocks on 2025-07-31, growing by 13503.0 shares to a total of 3.98 million shares. Yahoo Finance data shows the prior-month short interest on 2025-06-30 was 3.97 million shares. There was a rise of 0.34%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on April 22, 2024 when BofA Securities began covering the stock and recommended ‘”an Underperform”‘ rating along with a $150 price target.
